Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.72 |
| ▸ | DYRK2 | Q92630 | 9/20 | 0.72 |
| ▸ | DYRK1B | Q9Y463 | 8/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.72 |
| ▸ | DYRK3 | O43781 | 7/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.72 |
| ▸ | CDK2 | P24941 | 6/20 | 0.72 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.72 |
| ▸ | CDK9 | P50750 | 4/20 | 0.72 |
| ▸ | FYN | P06241 | 10/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28404217 | 0.97 | DYRK1A (0.68) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL3046666 | 0.87 | DYRK1A (0.59) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL15288602 | 0.86 | DYRK1A (0.70) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL2948779 | 0.85 | DYRK1A (0.68) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL477064 | 0.85 | DYRK1A (0.70) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL21210592 | 0.84 | DYRK1A (0.65) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL30027711 | 0.84 | DYRK1A (0.65) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL23535582 | 0.84 | DYRK1A (1.00) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL102942 | 0.84 | DYRK1A (1.00) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL102796 | 0.83 | DYRK1A (0.71) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111226956-B | Application of 3, 6-disubstituted imidazo [1,2-b ] pyridazine derivative in preparation of bactericide for inhibiting plant pathogenic fungi | 贵州医科大学 | 2021-10-26 | — | — | CN | claimed |
| CN-111226956-A | Application of 3, 6-disubstituted imidazo [1,2-b ] pyridazine derivative in preparation of bactericide | 贵州医科大学 | 2020-06-05 | — | — | CN | claimed |
| CN-120025336-A | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-05-23 | — | — | CN | disclosed |
| CN-115087657-B | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-01-21 | — | — | CN | disclosed |
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-23 | — | — | US | disclosed |
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-23 | — | — | US | disclosed |
| EP-4077332-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087657-A | LIN28 inhibitor and method of use thereof | 加利福尼亚大学董事会 | 2022-09-20 | — | — | CN | disclosed |
| CN-111226956-B | Application of 3, 6-disubstituted imidazo [1,2-b ] pyridazine derivative in preparation of bactericide for inhibiting plant pathogenic fungi | 贵州医科大学 | 2021-10-26 | — | — | CN | disclosed |
| WO-2021126779-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126779-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| EP-2176266-A2 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007025540-A2 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025540-A2 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | LIN28A, DDX21, BMI1 | DYRK1A 3932/4885DYRK2 3812/4885DYRK1B 3583/4885 |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 221/4885DYRK2 229/4885DYRK1B 235/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | DYRK1A 461/4885DYRK2 336/4885DYRK1B 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.